FDA Accepts Supplemental NDA for ONAPGO (Apomorphine Hydrochloride)
The FDA has accepted a supplemental NDA for ONAPGO, indicating progress in regulatory review.
Asset / Drug
Drug and asset intelligence for ONAPGO with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.